继发性中枢神经系统受累的大B细胞淋巴瘤的自体干细胞移植
本研究纳入本单位连续接受自体干细胞移植的102例继发性中枢神经系统大B细胞淋巴瘤患者,中位随访56个月,中位无进展生存期40个月、总生存期88个月,4年无进展生存率48%、总生存率57%。多因素分析显示移植时完全缓解和既往治疗线数≤2与更优的无进展生存期和总生存期显著相关。
要点
- 移植时完全缓解者无进展生存期(HR 0.278)和总生存期(HR 0.352)显著更优。
- 既往治疗线数≤2者无进展生存期(HR 0.485)和总生存期(HR 0.476)显著更优。
- 4年无进展生存率和总生存率分别为48%和57%。
核心结论
- 在最大的单中心研究中,自体干细胞移植与继发性中枢神经系统大B细胞淋巴瘤患者的持久缓解和延长生存相关。
- 移植时处于完全缓解和接受≤2线治疗的患者结局尤其好。
研究设计与样本
- 单中心研究,纳入本单位所有连续接受自体干细胞移植的继发性中枢神经系统大B细胞淋巴瘤患者,共102例。
- 移植时中位年龄56岁(范围21-71岁)。
- 主要终点为无进展生存期和总生存期。
主要发现
- 中位随访56个月(范围1-256个月),中位无进展生存期40个月,中位总生存期88个月。
- 4年无进展生存率48%,4年总生存率57%。
- 单因素分析中,移植时完全缓解、既往治疗线数≤2、乳酸脱氢酶正常和实质受累与无进展生存期改善显著相关;总生存期仅与移植时完全缓解和≤2线治疗相关。
- 多因素分析中,移植时完全缓解(HR 0.278;95%CI 0.153-0.506;P≤.0001)和≤2线治疗(HR 0.485;95%CI 0.274-0.859;P=.0131)与更优的无进展生存期显著相关。
- 多因素分析中,移植时完全缓解(HR 0.352;95%CI 0.186-0.663;P=.0013)和≤2线治疗(HR 0.476;95%CI 0.257-0.882;P=.0183)与总生存期改善相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Secondary central nervous system large B-cell lymphoma (SCNSL) is rare, with a generally poor prognosis. There is limited data about the role of autologous stem cell transplantation (ASCT) in these high-risk patients. We explored in this study treatment outcomes and prognostic factors for patients with SCNSL who underwent ASCT. We included all consecutive patients who underwent ASCT at our institution. Primary endpoints were progression-free survival (PFS) and overall survival (OS). One-hundred two patients were identified. Median age at transplant was 56 (range, 21-71) years. With a median follow-up of 56 (range, 1-256) months, the median PFS and OS were 40 and 88 months, respectively. The 4-year PFS and OS were 48% and 57%, respectively. In univariate analysis, complete remission (CR) at transplant, prior lines of therapy (≤2), normal lactate dehydrogenase, and parenchymal involvement were significantly associated with improved PFS. For OS, only CR at transplant and ≤2 prior lines of therapy were associated with improved survival. On multivariable analysis for PFS, CR at transplant (hazard ratio [HR], 0.278; 95% CI, 0.153-0.506; P ≤ .0001) and ≤2 prior lines of therapy (HR, 0.485; 95% CI, 0.274-0.859; P = .0131) were significantly associated with superior PFS. Similarly, CR at transplant (HR, 0.352; 95% CI, 0.186-0.663; P = .0013) and ≤2 prior lines of therapy (HR, 0.476; 95% CI, 0.257-0.882; P = .0183) were associated with improved survival. In the largest single-center study, our findings indicate that ASCT is associated with durable responses and prolonged survival in patients with SCNSL. Patients in CR at transplant and those who received ≤2 lines of therapy have particularly excellent outcomes.
引用
- Akin S, Hosing C, Khouri I, et al. Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement. Blood Adv. 2022. PMID: 35008100. doi:10.1182/bloodadvances.2021005602
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。